Effects of Mebendazole to Lenvatinib (drug) in liver cancer
Not Applicable
- Conditions
- Health Condition 1: K769- Liver disease, unspecified
- Registration Number
- CTRI/2020/06/026240
- Lead Sponsor
- Institute of Liver and Biliary Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1) Cirrhosis of Liver with HCC on imaging and/or biopsy or cytology
2) Child Pugh A, Child Pugh B < 8
3) Advanced HCC - as defined by BCLC - C
4) ECOG Performance Status 1-2
5) Adequately controlled blood pressure (BP) with up to 3 antihypertensive agents, defined as BP <=150/90 millimeters of mercury (mmHg) at screening and no change in antihypertensive therapy within 1 week prior to commencement of intervention.
6) Valid Consent
7) Age 18-70 years
Exclusion Criteria
1) Decompensated Cirrhosis
2) Child Pugh C, Child Pugh B > 7
3) HCC patients with a curative therapy (RFA/MWA or LT)
4) Prior systemic therapies (or) immunotherapy for HCC
5) ECOG Performance Status 3-4
6) Post Liver transplant HCC recurrence
7) Pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method